Tracking kidney disease treatment and biological changes over two years

This is a real-world study that tracks how well standard treatments work for people with primary membranous nephropathy, a kidney disease that causes protein to leak into urine. Researchers will monitor your treatment response over 24 months and collect blood samples to study genetic and biological changes that happen during treatment. The goal is to understand who benefits most from rituximab, a medication commonly used for this condition, and how the disease changes at the cellular level during therapy.

Primary membranous nephropathy is a serious kidney condition, and doctors need better ways to predict which patients will respond well to treatment. This study aims to fill that gap by studying how the disease and your body change during therapy, which could help doctors personalize treatment plans in the future.